High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial

Crohn's disease is associated with altered bone turnover that may be influenced by nutritional status, the systemic inflammatory response, cytokine production by circulating (peripheral blood) mononuclear cells (PBMC) and antioxidant micronutrient intake. High-dose fish oil is associated with reductions in disease relapse and inflammatory markers, and modulates PBMC function. The effect of fish oil plus antioxidants on bone turnover and PBMC function (the production of interferon-γ and prostaglandin E2) in Crohn's disease was investigated in a randomised-controlled trial. Patients with currently or recently raised biochemical markers of inflammation (C-reactive protein ≧6·9 mg/l or erythrocyte sedimentation rate ≧18 mm/h) received fish oil (providing 2·7 g/d EPA and DHA) and antioxidants (vitamins A, C and E, and Se) (n 31) or placebo (n 30) for 24 weeks. Bone turnover was assessed by measuring the concentrations of urinary deoxypyridinoline (bone resorption) and serum osteocalcin (bone formation). Fish oil plus antioxidants were associated with increases in EPA, DHA Se in plasma (all P<0·01), and with a reduction in interferon-γ production by mitogen-stimulated PBMC, which demonstrated a negative correlation with deoxypyridinoline/creatinine:osteocalcin ratio (r −0·33, P=0·009). There were no differences between the groups at 24 weeks in the response of deoxypyridinoline or osteocalcin or their ratio, or in nutritional status. Dietary supplementation in Crohn's disease with high intakes of EPA and DHA, as fish oil, plus antioxidants was associated with a modulated production of interferon-γ by PBMC but not altered indices of bone turnover.

[1]  P. Calder,et al.  Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. , 2004, The American journal of clinical nutrition.

[2]  P. Calder,et al.  Peripheral blood mononuclear cell fatty acid composition and inflammatory mediator production in adult Crohn's disease. , 2004, Clinical nutrition.

[3]  H. Weiler,et al.  The effect of dietary n-3 long-chain polyunsaturated fatty acids on femur mineral density and biomarkers of bone metabolism in healthy, diabetic and dietary-restricted growing rats. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[4]  P. Calder,et al.  Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status , 2004, Alimentary pharmacology & therapeutics.

[5]  C. Cooper,et al.  Inflammatory bowel disease and the risk of fracture. , 2003, Gastroenterology.

[6]  M. Barker,et al.  Is vitamin A consumption a risk factor for osteoporotic fracture? , 2003, Proceedings of the Nutrition Society.

[7]  P. Calder,et al.  Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. , 2003, The American journal of clinical nutrition.

[8]  Masaaki Takahashi,et al.  Comparison of biochemical markers of bone turnover and bone mineral density between hip fracture and vertebral fracture. , 2003, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[9]  P. Calder,et al.  Inhibition of tumour necrosis factor-alpha and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. , 2003, The British journal of nutrition.

[10]  Dongxu Sun,et al.  Dietary n‐3 Fatty Acids Decrease Osteoclastogenesis and Loss of Bone Mass in Ovariectomized Mice , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  Dongxu Sun,et al.  Protective role of n-3 lipids and soy protein in osteoporosis. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  F. Parhami.  Possible role of oxidized lipids in osteoporosis: could hyperlipidemia be a risk factor? , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  H. Steinhart,et al.  Antioxidant Vitamin Supplementation in Crohn's Disease Decreases Oxidative Stress: A Randomized Controlled Trial , 2003, American Journal of Gastroenterology.

[14]  K. Fearon,et al.  Effect of interleukin-2 on peripheral blood mononuclear cell cytokine production and the hepatic acute phase protein response. , 2002, Clinical immunology.

[15]  T. Taniguchi,et al.  Signaling crosstalk between RANKL and interferons in osteoclast differentiation , 2002, Arthritis research.

[16]  N. Takahashi,et al.  Regulatory mechanisms of osteoblast and osteoclast differentiation. , 2002, Oral diseases.

[17]  M. Silverberg,et al.  Risk Factors for Low Bone Density in Crohn's Disease , 2002, Inflammatory bowel diseases.

[18]  J. Penninger,et al.  RANK-L and RANK: T cells, bone loss, and mammalian evolution. , 2002, Annual review of immunology.

[19]  J. Sterne,et al.  Dietary antioxidants and asthma in adults: population-based case-control study. , 2001, American journal of respiratory and critical care medicine.

[20]  P. Pietschmann,et al.  Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures , 2001, Experimental Gerontology.

[21]  T. Suda,et al.  Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.

[22]  M. Kacena,et al.  Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. , 2001, Cytokine & growth factor reviews.

[23]  N. Kamatani,et al.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. , 2001, Arthritis & Rheumatism.

[24]  P. Calder.  N-3 polyunsaturated fatty acids, inflammation and immunity: pouring oil on troubled waters or another fishy tale? , 2001 .

[25]  T. Terano.  Effect of ω3 Polyunsaturated Fatty Acid Ingestion on Bone Metabolism and Osteoporosis , 2001 .

[26]  T. Terano.  Effect of omega 3 polyunsaturated fatty acid ingestion on bone metabolism and osteoporosis. , 2001, World review of nutrition and dietetics.

[27]  R. Eastell,et al.  The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[28]  E. Bassey,et al.  Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone. , 2000, The British journal of nutrition.

[29]  S. Blum,et al.  Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. , 2000, JPEN. Journal of parenteral and enteral nutrition.

[30]  J. Eritsland.  Safety considerations of polyunsaturated fatty acids. , 2000, The American journal of clinical nutrition.

[31]  M. Kruger,et al.  Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[32]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[33]  M. McKenna,et al.  Bone Density, Vitamin D Status, and Disordered Bone Remodeling in End-Stage Chronic Liver Disease , 1999, Calcified Tissue International.

[34]  J. Hampe,et al.  Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease , 1999, The Lancet.

[35]  G. Gericke,et al.  Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis , 1998, Aging.

[36]  M. Vos,et al.  Bone and joint diseases in inflammatory bowel disease , 1998 .

[37]  P. Yaqoob,et al.  Monounsaturated fats and immune function. , 1998, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[38]  M. De Vos,et al.  Review article: bone and joint diseases in inflammatory bowel disease. , 1998, Alimentary Pharmacology and Therapeutics.

[39]  K. Fearon,et al.  Effect of interleukin-4 on pro-inflammatory cytokine production and the acute phase response in healthy individuals and in patients with cancer or multiple organ failure. , 1998, Clinical science.

[40]  L. Mosekilde,et al.  Inflammatory bowel disease and osteoporosis. , 1997, Scandinavian journal of gastroenterology.

[41]  M. Campieri,et al.  Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. , 1996, The New England journal of medicine.

[42]  M. Grisham.  Oxidants and free radicals in inflammatory bowel disease , 1994, The Lancet.

[43]  I. Morita,et al.  Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. , 1994, Prostaglandins, leukotrienes, and essential fatty acids.

[44]  C. Dinarello,et al.  Dietary supplementation with n‐3 fatty acids suppresses interleukin‐2 production and mononuclear cell proliferation , 1993, Journal of leukocyte biology.

[45]  D. Rampton,et al.  Inflammatory bowel disease--a radical view. , 1993, Gut.

[46]  H. Hodgson,et al.  Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. , 1992, Gut.

[47]  T. Toyota,et al.  The role of interferon gamma in the pathogenesis of Crohn's disease. , 1992, Gastroenterologia Japonica.

[48]  Dietary reference values for food energy and nutrients for the United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy. , 1991, Reports on health and social subjects.

[49]  D. Hollander,et al.  Defective in vitro gamma interferon production and elevated serum immunoreactive thymosin beta 4 levels in patients with inflammatory bowel disease. , 1988, Clinical immunology and immunopathology.

[50]  M. Campieri,et al.  A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. , 1986, Gastroenterology.

[51]  M. Devoto,et al.  Importance of laboratory parameters in the evaluation of Crohn's disease activity. , 1986, Journal of clinical gastroenterology.

[52]  N. Hiwatashi,et al.  Cytokine production in inflammatory bowel disease. , 1985, Journal of clinical & laboratory immunology.

[53]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.